263. Cerebrotendinous xanthomatosis Clinical trials / Disease details


Clinical trials : 6 Drugs : 11 - (DrugBank : 2) / Drug target genes : 2 - Drug target pathways : 4

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-205157
03/8/202013/02/2020An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3) Cerebrotendinous xanthomatosisIntervention name : FPF1011
INN of the intervention : Chenodeoxycholic acid
Dosage And administration of the intervention : Dose of chenodeoxycholic acid is 750 mg/day for patients aged 20 or older, and 15 mg/kg/day under ages 20, administered orally in three divided doses a day.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -
Fujimoto Pharmaceutical CorporationNULLrecruiting0BOTH5Phase 3Japan
2NCT04270682
(ClinicalTrials.gov)
January 31, 202012/2/2020Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)A Phase 3 Study to Evaluate the Effects of Chenodeoxycholic Acid in Adult and Pediatric Patients With Cerebrotendinous XanthomatosisCTXDrug: Blinded CDCA 250 mg TID;Drug: Placebo;Drug: Open-Label CDCA 250 mg TID;Drug: Rescue Medication CDCA 250 mg TID;Drug: CDCA Weight-Based Dose TIDTravere Therapeutics, Inc.NULLRecruiting1 MonthN/AAll12Phase 3United States;Brazil
3NCT04218006
(ClinicalTrials.gov)
December 1, 20192/1/2020A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX)A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX) in Families With Kinship Bonds and at Least One Homozygous PatientXanthomatosis, CerebrotendinousGenetic: Mutation AnalysisTRPHARMKlinar CRO;Damagen Genetic Diagnostic CenterEnrolling by invitationN/AN/AAll800Turkey
4NCT01613898
(ClinicalTrials.gov)
August 201022/5/2012Evaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous XanthomatosisEvaluation of Carotid IMT and Atherogenic Risk Factors in Patients With Cerebrotendinous XanthomatosisCerebrotendinous Xanthomatosis (CTX)Biological: Blood testsSheba Medical CenterNULLRecruiting10 YearsN/ABoth17N/AIsrael
5NCT00018694
(ClinicalTrials.gov)
October 19993/7/2001Cholestanol in HumansBiologic Significance of Cholestanol in ManCerebrotendinous XanthomatosisDrug: Chenodeoxycholic AcidDepartment of Veterans AffairsNULLWithdrawn5 Years80 YearsBoth0N/AUnited States
6NCT00004346
(ClinicalTrials.gov)
January 199618/10/1999Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous XanthomatosisEffects of Diet and Medication in Patients With Cerebrotendinous Xanthomatosis (CTX)Cerebrotendinous XanthomatosisDrug: chenodeoxycholic acid;Drug: lovastatinNational Center for Research Resources (NCRR)Oregon Health and Science UniversityRecruitingN/AN/ABoth5Phase 2United States